4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
Shafer, C.M., Lindvall, M., Bellamacina, C., Gesner, T.G., Yabannavar, A., Jia, W., Lin, S., Walter, A.(2008) Bioorg Med Chem Lett 18: 4482-4485
- PubMed: 18672368 
- DOI: https://doi.org/10.1016/j.bmcl.2008.07.061
- Primary Citation of Related Structures:  
3DCV - PubMed Abstract: 
A series of 4-(4-hydroxyphenyl)-6-phenylpyrimidin-2(1H)-ones were identified by HTS as inhibitors of CDC7. Molecular modeling and medicinal chemistry techniques were employed to explore the SAR for this series with a focus on removing potential metabolic liabilities and improving cellular potency.
Organizational Affiliation: 
Oncology Division, Novartis Institutes of Biomedical Research, 4560 Horton Street, Emeryville, CA 94608, USA. cynthia_shafer@chiron.com